Integrated BioPharma, Inc. engages in the manufacture, distribution, marketing, and sale of vitamins, nutritional supplements and herbal products. It operates through the following segments: Contract Manufacturing, Branded Proprietary Products, and Other Nutraceutical Businesses. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers. The Branded Proprietary Products segment distributes nutritional products through mass market, grocery, drug and vitamin retailers. The Other Nutraceutical Businesses segment sells private label MDC products, as well as AgroLabs products. The company was founded by E. Gerald Kay in March 1980 and is headquartered in Hillside, NJ.

Company profile
Ticker
INBP
Exchange
Website
CEO
Riva Kay Sheppard / Christina Kay
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHEM INTERNATIONAL INC, INTEGRATED HEALTH TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
Manhattan Drug Company, Inc. • AgroLabs, Inc. • IHT Health Products, Inc. • Vitamin Factory, Inc. • IHT Properties, Inc. • MDC Warehousing and Distribution, Inc. • InB:Paxis Pharmaceuticals, Inc. ...
IRS number
222407475
INBP stock data
Investment data
Securities sold
Number of investors
Calendar
12 May 22
9 Aug 22
30 Jun 23
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 21 | Jun 20 | Jun 19 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jun 22 | Robert Canarick | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0 | 50,000 |
20 Jun 22 | Milmoe William H. | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0 | 50,000 |
20 Jun 22 | Eric J Friedman | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0 | 50,000 |
20 Jun 22 | Damon DeSantis | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0 | 50,000 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
Financial reports
Current reports
8-K
Entry into a Material Definitive Agreement
15 Jul 22
8-K
Integrated BioPharma Announces Change in Directors
21 Jun 22
8-K
Results of Operations and Financial Condition
12 May 22
8-K
Results of Operations and Financial Condition
10 Feb 22
8-K
Submission of Matters to a Vote of Security Holders
29 Nov 21
8-K
Results of Operations and Financial Condition
10 Nov 21
8-K
Results of Operations and Financial Condition
2 Sep 21
8-K
Termination of a Material Definitive Agreement
7 Jul 21
8-K
Results of Operations and Financial Condition
13 May 21
8-K
Integrated BioPharma Announces Launch of Investors Website
8 Apr 21
Registration and prospectus
S-8
Registration of securities for employees
28 Dec 18
D
$5.35M in debt / securities to be acquired, sold $5.35M, 1 investor
10 Jul 12
25
Voluntary exchange delisting
12 Apr 09
424B3
Prospectus supplement
5 May 08
S-3/A
Shelf registration (amended)
15 Apr 08
S-3
Shelf registration
20 Mar 08
REGDEX
Notice of sale of securities
6 Mar 08
RW
Registration withdrawal request
22 Aug 07
Other
UPLOAD
Letter from SEC
3 Aug 08
EFFECT
Notice of effectiveness
1 May 08
CORRESP
Correspondence with SEC
29 Apr 08
UPLOAD
Letter from SEC
21 Apr 08
UPLOAD
Letter from SEC
26 Mar 08
UPLOAD
Letter from SEC
26 Mar 08
UPLOAD
Letter from SEC
12 Mar 08
EFFECT
Notice of effectiveness
10 Jul 07
CORRESP
Correspondence with SEC
9 Feb 05
UPLOAD
Letter from SEC
17 Jan 05
Ownership
4
INTEGRATED BIOPHARMA / Damon DeSantis ownership change
21 Jun 22
3
INTEGRATED BIOPHARMA / Damon DeSantis ownership change
21 Jun 22
4
INTEGRATED BIOPHARMA / ERIC J FRIEDMAN ownership change
21 Jun 22
4
INTEGRATED BIOPHARMA / William H. Milmoe ownership change
21 Jun 22
4
INTEGRATED BIOPHARMA / Robert Canarick ownership change
21 Jun 22
4/A
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
11 May 22
4
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
6 May 22
4
INTEGRATED BIOPHARMA / William H. Milmoe ownership change
4 Nov 21
4
INTEGRATED BIOPHARMA / CARL DESANTIS ownership change
4 Nov 21
4
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
4 Nov 21